Evaluating the effect of Valerian on irritable bowel syndrome

Evaluating the effect of Valerian (Valeriana officinalis) supplementation on the symptoms severity and quality of life in patients with irritable bowel syndrome: A randomized and double-blind clinical trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20210427051098N3

Enrollment

Registered

2023-11-18

Start date

2023-10-23

Completion date

Unknown

Last updated

2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Symptoms Severity and quality of life in patients with irritable bowel syndrome. Other and unspecified irritable bowel syndrome

Interventions

Intervention 1: Intervention group: 500 mg capsule of dried Valerian (Valeriana officinalis) powder twice daily (1000 mg overall). Intervention 2: Control group: 500 mg capsule of starch powder twice

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1- Age 18 to 65 years 2- Patients with irritable bowel syndrome according to the diagnosis of a gastroenterologist according to ROME-IV criteria

Exclusion criteria

Exclusion criteria: Dietary changes during the study Unwillingness to continue attending the study Pregnancy or breastfeeding during the study Hospitalization Suffering from certain diseases such as any active stomach-enteric disease or taking certain medicines Having an allergy to herbal products

Design outcomes

Primary

Measure	Time frame
Symptoms severity of irritable bowel syndrome. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: IBS-Severity Scoring System (IBS-SSS) questionnaire.;The quality of life in patients with irritable bowel syndrome. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: Irritable Bowel Syndrome Quality of Life Questionnaire.	—

Measure

Time frame

Symptoms severity of irritable bowel syndrome. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: IBS-Severity Scoring System (IBS-SSS) questionnaire.;The quality of life in patients with irritable bowel syndrome. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: Irritable Bowel Syndrome Quality of Life Questionnaire.

—

Secondary

Measure	Time frame
Anxiety and depression. Timepoint: At the beginning of the study and after 8 weeks of the intervention. Method of measurement: Hospital Anxiety and Depression Scale questionnaire.;Visceral Sensitivity. Timepoint: At the beginning of the study and after 8 weeks of the intervention. Method of measurement: Visceral Sensitivity Index questionnaire.;Patient Health. Timepoint: At the beginning of the study and after 8 weeks of the intervention. Method of measurement: Patient Health Questionnaire (PHQ)-12.;Sleep quality. Timepoint: At the beginning of the study and after 8 weeks of the intervention. Method of measurement: Pittsburgh Sleep Quality Index questionnaire (PSQI).	—

Measure

Time frame

Anxiety and depression. Timepoint: At the beginning of the study and after 8 weeks of the intervention. Method of measurement: Hospital Anxiety and Depression Scale questionnaire.;Visceral Sensitivity. Timepoint: At the beginning of the study and after 8 weeks of the intervention. Method of measurement: Visceral Sensitivity Index questionnaire.;Patient Health. Timepoint: At the beginning of the study and after 8 weeks of the intervention. Method of measurement: Patient Health Questionnaire (PHQ)-12.;Sleep quality. Timepoint: At the beginning of the study and after 8 weeks of the intervention. Method of measurement: Pittsburgh Sleep Quality Index questionnaire (PSQI).

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZohreh Khosravani Shooli

Yazd University of Medical Sciences

Zoh.khosravani@gmail.com+98 35 3820 9100

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Jun 11, 2026